{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:42:04Z","timestamp":1792705324688,"version":"4.5.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.49040","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T11:32:14Z","timestamp":1645183934000},"page":"e2149040","source":"Crossref","is-referenced-by-count":122,"title":["Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer"],"prefix":"10.1001","volume":"5","author":[{"given":"Niharika B.","family":"Mettu","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Shu","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler J.","family":"Zemla","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur R.","family":"Halfdanarson","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimini A.","family":"Breakstone","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Lifespan Cancer Institute, Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Boland","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oxana V.","family":"Crysler","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Nixon","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Bolch","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology Clinical Research, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Niedzwiecki","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Elsing","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert I.","family":"Hurwitz","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina"},{"name":"Product Development Oncology, Genentech Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan G.","family":"Fakih","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, City of Hope National Medical Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"issue":"26","key":"zoi211348r1","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency.","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi211348r2","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair\u2013deficient or microsatellite instability\u2013high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi211348r3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair\u2013deficient\/microsatellite instability\u2013high metastatic colorectal cancer.","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"23","key":"zoi211348r4","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer.","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi211348r5","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi211348r6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors.","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"issue":"6801","key":"zoi211348r7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases.","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"issue":"18","key":"zoi211348r8","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression.","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"zoi211348r9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00262-007-0441-x","article-title":"The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.","volume":"57","author":"Osada","year":"2008","journal-title":"Cancer Immunol Immunother"},{"issue":"20","key":"zoi211348r10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"zoi211348r11","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC.","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"10189","key":"zoi211348r12","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"zoi211348r13","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi211348r14","first-page":"33","article-title":"Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and\/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).","author":"Bendell","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi211348r15","first-page":"35","article-title":"Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)\u2013high metastatic colorectal cancer (mCRC).","author":"Hochster","year":"2017","journal-title":"J Clin Oncol"},{"key":"zoi211348r16","author":"Grothey","year":"2018"},{"key":"zoi211348r17"},{"issue":"1","key":"zoi211348r18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"issue":"2","key":"zoi211348r19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"28","key":"zoi211348r21","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","article-title":"Design issues of randomized phase II trials and a proposal for phase II screening trials.","volume":"23","author":"Rubinstein","year":"2005","journal-title":"J Clin Oncol"},{"issue":"20","key":"zoi211348r22","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer.","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi211348r23","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO.26 study.","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9863","key":"zoi211348r24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"zoi211348r25","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi211348r26","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603).","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi211348r27","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.","volume":"52","author":"Lee","year":"2020","journal-title":"Exp Mol Med"},{"issue":"3","key":"zoi211348r28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/bjc.2017.376","article-title":"Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.","volume":"118","author":"Brown","year":"2018","journal-title":"Br J Cancer"},{"issue":"1","key":"zoi211348r29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12885-017-3825-0","article-title":"Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer.","volume":"18","author":"O\u2019Donnell","year":"2018","journal-title":"BMC Cancer"},{"issue":"8","key":"zoi211348r30","doi-asserted-by":"publisher","first-page":"e1188","DOI":"10.1634\/theoncologist.2020-0161","article-title":"Regorafenib and nivolumab or pembrolizumab combination and circulating tumor DNA response assessment in refractory microsatellite stable colorectal cancer.","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"issue":"2","key":"zoi211348r31","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s10620-020-06203-8","article-title":"Comparison of immune microenvironment between colon and liver metastatic tissue in colon cancer patients with liver metastasis.","volume":"66","author":"Zhou","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"10","key":"zoi211348r32","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"zoi211348r33","first-page":"39","article-title":"Tissue and plasma tumor mutation burden (TMB) as predictive biomarkers in the CO.26 trial of durvalumab + tremelimumab (D+T) versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).","author":"Loree","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi211348r34","first-page":"18","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"zoi211348r20","unstructured":"National Cancer Institute, National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. US Department of Health and Human Services; 2009. Accessed July 1, 2020. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2789172\/mettu_2022_oi_211348_1644593861.84373.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T11:32:21Z","timestamp":1645183941000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2789172"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.49040","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,18]]}}}